Engineering human ventricular heart tissue based on macroporous iron oxide scaffolds. (1st April 2019)

• Record Type: Journal Article
• Authors: Yang, Hui; Wei, Lai; Liu, Chen; Zhong, Weiyi; Li, Bin; Chen, Yuncan; Han, Rui; Zhuang, Jiexian; Qu, Jianxun; Tao, Hongyue; Chen, Haiyan; Xu, Chen; Liang, Qianqian; Lu, Chao; Qian, Ruizhe; Chen, Sifeng; Wang, Wenshuo; Sun, Ning
• Is Part Of: Acta biomaterialia. Volume 88(2019)
• Page Start: 540
• Page End: 553
• Publication Date: 2019-04-01
• Subjects: Iron oxide scaffolds -- Ventricular myocytes -- Engineered heart tissues -- Myocardial infarction; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2019.02.024
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Myocardial infarction (MI) is a primary cardiovascular disease threatening human health and quality of life worldwide. The development of engineered heart tissues (EHTs) as a transplantable artificial myocardium provides a promising therapy for MI. Since most MIs occur at the ventricle, engineering ventricular-specific myocardium is therefore more desirable for future applications. Here, by combining a new macroporous 3D iron oxide scaffold (IOS) with a fixed ratio of human pluripotent stem cell (hPSC)-derived ventricular-specific cardiomyocytes and human umbilical cord-derived mesenchymal stem cells, we constructed a new type of engineered human ventricular-specific heart tissue (EhVHT). The EhVHT promoted expression of cardiac-specific genes, ion exchange, and exhibited a better Ca 2+ handling behaviors and normal electrophysiological activity in vitro . Furthermore, when patched on the infarcted area, the EhVHT effectively promoted repair of heart tissues in vivo and facilitated the restoration of damaged heart function of rats with acute MI. Our results show that it is feasible to generate functional human ventricular heart tissue based on hPSC-derived ventricular myocytes for the treatment of ventricular-specific myocardium damage. Statement of significance: We successfully generated highly purified homogenous human ventricular myocytes and developed a method to generate human ventricular-specific heart tissue (EhVHT) based on three-dimensional iron oxide scaffolds. The EhVHT promoted expression of cardiac-specific genes, ion exchange, and exhibited a better Ca 2+ handling behaviors and normal electrophysiological activity in vitro . Patching the EhVHT on the infarct area significantly improved cardiac function in rat acute MI models. This EhVHT has a great potential to meet the specific requirements for ventricular damages in most MI cases and for screening drugs specifically targeting ventricular myocardium.